Missing Markets for Innovation: Evidence from New Uses for Existing Drugs
We investigate missing markets for innovation: contexts where intellectual property rights necessary to incentivize research investment are either unavailable or unenforceable. A simple theoretical model formalizes the conditions that yield missing investment. We identify an empirical setting—research into new uses for existing drugs— with sharp variation in the enforceability of intellectual property rights on comparable inventions. We show that when intellectual property rights become unenforceable, research investment and commercialization nearly cease. Estimates of the value of this missing investment are in the trillions of dollars. We discuss the implications of these findings for the design of innovation policy.
-
-
Copy CitationEric Budish, Maya M. Durvasula, Benjamin N. Roin, and Heidi L. Williams, "Missing Markets for Innovation: Evidence from New Uses for Existing Drugs," NBER Working Paper 34222 (2025), https://doi.org/10.3386/w34222.Download Citation
-
Related
Mentioned in the News
More from the NBER
In addition to working papers, the NBER disseminates affiliates’ latest findings through a range of free periodicals—the NBER Reporter, the NBER Digest, the Bulletin on Health, the Bulletin on the Economics of Alzheimer's, and the Bulletin on Entrepreneurship—as well as research spotlights, lectures, and panel videos.